BackgroundAmeloblastoma is a slow-growing neoplasm of the jaw, for which the standard treatment is surgical removal of the lesion with high recurrence rates and elevated morbidity. Systemic therapy is not established in the literature.Case presentationWe present a case of a 29-year-old woman diagnosed with an ameloblastoma of the left mandible who had been subjected to several surgical procedures over twenty years due to multiple local recurrences. Molecular testing revealed a BRAF V600E mutation, and vemurafenib was started. She experienced complete resolution of symptoms related to the disease, and image scans evidenced continuous shrinkage of the neoplastic lesion after eleven months of therapy.ConclusionThis is the first report showing clinical benefit and radiological response with vemrafenib for recurrent ameloblastoma. Targeted therapy addressing BRAF V600E mutation has the potential to change clinical practice of this rare disease.

PURPOSE: To comparatively evaluate the accuracy of newer intraocular lens (IOL) calculation formulas and common third-generation formulas after Wang-Koch adjustment in the prediction of postoperative refraction in highly myopic eyes. METHODS: This was a retrospective study including eyes with high myopia that had uncomplicated cataract surgery with implantation of an AcrySof MA60MA IOL (power range: −5.00 to +5.00 diopters [D]) (Alcon Laboratories, Inc). All patients underwent optical biometry (Carl Zeiss IOLMaster 500 and IOLMaster 700, and Allegro Biograph) and the postoperative spherical equivalent for the implanted IOL was estimated using SRK/T, Holladay 1 (both Wang-Koch adjusted), Haigis, Barrett Universal II, Kane, Ladas, and Hill-RBF v2.0 formulas. Outcomes included the median absolute prediction error (MedAE) and the proportion of eyes within ±0.25, ±0.50, and ±1.00 D of the preoperative prediction. RESULTS: Eighty-two eyes with a mean axial length of 30.89 ± 1.85 mm were included. The MedAE in ascending order was Hill-RBF v2.0 0.31 D, Kane 0.33 D, Barrett 0.36 D, Holladay I wk 0.37 D, SRK/T wk 0.37 D, Holladay I wk 0.43 D, Haigis ULIB 0.54 D, and Ladas 0.61 D. The formula with the lowest MedAE (Hill-RBF v2.0) yielded a prediction error within ±0.25, ±0.50, and ±1.00 D in 43.1%, 70.6%, and 94.1% of cases, respectively. CONCLUSIONS: Recent formulas such as Barrett Universal II, Kane, and Hill-RBF v2.0 and Wang-Koch adjusted formulas perform well in this subset of patients with high myopia. The Hill-RBF v2.0 formula had the lowest MedAE and highest proportion of eyes within ±0.25, ±0.50, and ±1.00 D of the predicted target. [ J Refract Surg . 2021;37(3):207–211.]

OBJECTIVE: To describe a series of endoleak cases and their respective classification. MATERIALS AND METHODS: The authors developed a retrospective study of endoleaks diagnosed at their institution in the period between 2005 and 2009. Twenty cases were included to illustrate the different types of endoleaks. RESULTS: Seventy percent of the patients were men, and the ages ranged from 43 to 91 years (mean, 76.3 years). Thirteen cases were observed in the infrarenal abdominal aorta, four in the thoracic aorta, two in the iliac artery, and one in the carotid territory. Ultrasonography was the method utilized for diagnosis in three cases, and computed tomography in the other 17 cases. 5. Professor Doctor, Division of Radiology, Coordinator of the or heart wall, that is larger than 50% of the presumed normal diameter (1) . Among aortic aneurysms, 90 % to 95% are located in the abdominal aorta below the renal arteries bifurcation (2) .The prevalence of abdominal aortic aneurysms increases with age, affecting approximately 6% of individuals after 65 years of age (3) . The mean age at diagnosis is between 65 and 75 years, with male predominance (4) . Currently, its incidence is increasing as a consequence of the global population aging (5) .Chagas Neto FA, Barreto ARF, Reis HF, Bernardes JPG, Leitão JPC, Lucena AF, Muglia VF, Elias Junior J. The value of diagnostic imaging in the classification of endoleaks as a complication of endoluminal grafting of aortic aneurysms. Radiol Bras. 2010;43(5):289-294.

Intravitreal injections of antivascular endothelial growth factors have been considered a milestone in the treatment of neovascular age-related macular degeneration (nAMD). However, the increasing incidence of AMD and the burden of visits and injections overcharge both the patient and the healthcare systems. Real-world solutions depend on treatment protocols aimed at optimizing the number of clinical visits while guaranteeing good functional outcomes. We performed a retrospective analysis of 72 eyes from 63 naïve patients diagnosed with nAMD that underwent a fixed intravitreal protocol consisting of bimonthly injections after a three-month loading dose, with either Aflibercept or Ranibizumab (no predefined criteria for treatment selection). Best corrected visual acuity (BCVA) and optical coherence tomography were analyzed at baseline and during follow-up clinical visits (months 3, 6, 12, and 18). From the included participants, 42 followed a fixed regimen with Aflibercept and 30 with Ranibizumab. At the 12-month visit, there was not a statistically significant difference in the mean change of BCVA between the two groups (p=0.121); however, the mean difference in the central retinal thickness was significantly superior in the Aflibercept group (-142.2 versus -51.5, p=0.011). The described fixed regimen seems to be efficient in the treatment of nAMD in a clinical practice setting.